A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Project: Research

Project Details

StatusActive
Effective start/end date6/04/205/04/25

Keywords

  • Clinical trial
  • chemotherapy
  • endometrial cancer
  • treatment efficacy